Treatment guidelines for rare, early-onset conditions associated with epileptic seizures: a literature review on Rett syndrome and tuberous sclerosis complex.

Publication Year: 2024

DOI:
10.1186/s13023-023-02994-x

PMCID:
PMC10895812

PMID:
38409029

Journal Information

Full Title: Orphanet J Rare Dis

Abbreviation: Orphanet J Rare Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateNot applicable to this manuscript. Consent for publicationNot applicable to this manuscript. Competing interestsThis study was funded by GW Global Services (International) Ltd. Editorial and medical writing services were provided by Costello Medical. S. Amin, has provided consultancy and speaker services, and has participated in events and studies, for GW Global Services (International) Ltd; Medtronic Limited, Boston Scientific, Novartis, PTC therapeutics and Desitin; I. Newell, employee of Costello Medical; B. Ruban-Fell, employee of Costello Medical; J. Evans, employee of Costello Medical; K. Vyas, employee of GW Global Services (International) Ltd; C. Nortvedt, employee of GW Global Services (International) Ltd; R.F.M. Chin, has provided consultancy and speaker services, and has participated in events and studies, for GW Global Services (International) Ltd, Eisai, Zogenix, Neopharm Group and The Rize Medical Cannabis and Life Sciences UCITS ETF. Competing interests This study was funded by GW Global Services (International) Ltd. Editorial and medical writing services were provided by Costello Medical. S. Amin, has provided consultancy and speaker services, and has participated in events and studies, for GW Global Services (International) Ltd; Medtronic Limited, Boston Scientific, Novartis, PTC therapeutics and Desitin; I. Newell, employee of Costello Medical; B. Ruban-Fell, employee of Costello Medical; J. Evans, employee of Costello Medical; K. Vyas, employee of GW Global Services (International) Ltd; C. Nortvedt, employee of GW Global Services (International) Ltd; R.F.M. Chin, has provided consultancy and speaker services, and has participated in events and studies, for GW Global Services (International) Ltd, Eisai, Zogenix, Neopharm Group and The Rize Medical Cannabis and Life Sciences UCITS ETF."

Evidence found in paper:

"Funding This study was sponsored by GW Global Services (International) Ltd. Support for third-party writing assistance for this article, provided by Eleanor Thurtle, MChem, Costello Medical, UK, was funded by GW Global Services (International) Ltd in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3)."

Evidence found in paper:

"Trial registration Not applicable."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025